Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Jean‐Yves Douillard, Salvatore Siena, James T. Cassidy, +17

Journal of Clinical Oncology

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer

Johan Vansteenkiste, Jean‐Luc Canon, Filippo de Braud, +16

Journal of Thoracic Oncology

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

David Miles, David Cameron, Igor Bondarenko, +14

European Journal of Cancer

First-line TherapyBreast OncologyProspective Biomarker EvaluationMedicinePharmacology +6

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

Eric Van Cutsem, Manuel Hidalgo, Jean‐Luc Canon, +11

International Journal of Cancer

Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?

Catherine Hubert, Christine Sempoux, Yves Horsmans, +6

Liver International

A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial

Rachel Galot, Christophe Le Tourneau, Esma Saâda-Bouzid, +22

European Journal of Cancer

Eortc-hncg-1559 Upstream TrialMalignant DiseaseMedicinePathologyPhase Ii Study +6

Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies

Marc André, Étienne Baudoux, Dominique Bron, +10

Transfusion

A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer

Giuseppe Curigliano, Gilles Romieu, Mario Campone, +12

Breast Cancer Research and Treatment

Breast OncologyMedicineImmunologyImmune Checkpoint InhibitorBreast Cancer +8

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

Steven Limentani, Mario Campone, Thierry Dorval, +17

Breast Cancer Research and Treatment

Radiation OncologyTumor ImmunologyBreast OncologyHer2-overexpressing TumorsBreast Cancer Patients +11

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer

Fátima Cardoso, Jean‐Luc Canon, Dino Amadori, +8

The Breast